Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MALT-RO
NCT07554898Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Complete Remission Rate at 6 months and Incidence of Adverse Events at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT07554898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554898.